Mercia Asset Management Share Discussion Threads

[steve3sandal] 18/12/2017 19:54

Forgive me if you know all this.
I was warming to Mercia at this price, until this RNS. In chartist speak we hav3 a bowl forming. But I really really don’t like the bit about, if at first the options don’t vest because we mucked up, keep the options....etc.
I found Mercia from reading some EIS promotional material...opportunity to invest in selected companies etc. It became clear to me that Mercia invest ahead and alongside and collect management fees come what may. I would rather back the field and collect fees so Mercia rather than the investee Cos caught my interest.
Not now.

[p1nkfish] 18/12/2017 17:18

I have been ing over a period as the portfolio looks very useful to me and Merc relatively unloved.

[turbocharge] 18/12/2017 15:15

18 December 2017

Amendment to Share Options

At the time of the Company's IPO on 18 December 2014 ("Admission") options (the "Options") over 1,000,000 new Ordinary shares with a nominal value of 0.001p pence each in the capital of the Company ("Ordinary Shares") were awarded to each of Dr. Mark Payton, Chief Executive Officer and Martin Glanfield, Chief Financial Officer, both directors of Mercia (together the "Executive Directors"). The Options were awarded pursuant to the 2014 Mercia Company Share Option Plan ("Mercia CSOP").

The Options were subject to a performance condition which would have been satisfied if the total shareholder return (being the increase in the price of an Ordinary Share from a 50.0 pence base value plus any dividend yield) from Admission to the third anniversary of Admission was not less than 9.55 pence (being 6% compound per annum). The exercise price (being the price per share payable on the exercise of such options) would therefore have been 59.55 pence had the performance condition been satisfied.

The performance condition has not been satisfied on the third anniversary of Admission. However, having considered the matter at length and pursuant to the rules of the Mercia CSOP, the Company's Remuneration Committee has elected to vary the vesting period in which the performance condition of the Options has to be satisfied. Accordingly, the Options will now vest on the fifth anniversary of Admission if the total shareholder return from Admission to the fifth anniversary of Admission is not less than 9.55 pence. If the performance condition is satisfied on the fifth anniversary of Admission the exercise price will be 59.55 pence. The Remuneration Committee considers that this is the most appropriate way of continuing to align the interests of the Executive Directors with the shareholders of the Company, whilst continuing to provide a strong incentive, thereby facilitating the retention of high calibre individuals.

[cheshire man] 12/12/2017 09:43

Decent buying going on here,,,,,happy to tuck away and see where it takes me :-)

[masurenguy] 07/12/2017 01:37

Mercia Technologies
Advice Buy: Why Long-term potential for those with patience and a healthy risk appetite.

[spectoacc] 06/12/2017 08:59

Woodford may not agree, but I just think this is such a better bet than ALM, being on a reasonable discount to NAV and with a proven track record (for the managers at least).

[wan] 27/11/2017 08:17

Interesting recent news from a Mercia portfolio company, MIP Diagnostics-

21st November 2017

Breakthrough Discovery In Diagnostic Tools That Can Replace Antibodies

In a newly released article “A comparison of the performance of molecularly imprinted polymer nanoparticles for small molecule targets and antibodies in the ELISA format” the researchers successfully demonstrated that polymer nanoparticles produced by the molecular imprinting technique (MIP nanoparticles) can bind to the target molecule with the same or higher affinity and specificity than widely used commercially available antibodies and against challenging targets.

Additionally, their ease of manufacture, short lead time, high affinity and the lack of requirement for cold chain logistics make them an attractive alternative to traditional antibodies for use in immunoassays.

The robust nature of MIP nanoparticles makes them ideal reagents for a wide range of applications including point-of-care diagnostics and in field based testing.

They can withstand harsh environments, such as extremes of pH and temperature, seawater and can even function in organic solvents.

Full article -

[aishah] 14/11/2017 07:40

Update reads well:


"The Life Sciences & Biosciences portfolio is progressing at an impressive rate as a result of close collaboration with our 19 university partners and a highly experienced Investment Team, both of which provide an important source of highly disruptive deal flow opportunities. All five of the existing sector portfolio have come through our managed funds, with four of these via our university partnerships and one through the Investment Team's personal networks. Securing the recent new partnership with the University of Edinburgh will build on our existing track record of sourcing and shaping exciting investment prospects.

"There is tremendous potential within the portfolio which Mercia is nurturing to build shareholder value. I look forward to providing future updates where we will detail the continued and positive progress of our sector portfolio."

[turbocharge] 07/11/2017 09:59

5 Bullish signals on 6 Nov 2017 (33.63)

Price Crosses Moving Average (21-day)
Relative Strength Index (RSI)
Moving Average Convergence/Divergence (MACD)
Momentum
Williams %R

[baggariddim] 06/11/2017 21:51

Thinking of investing here,does anyone have links to any broker notes.Thanks.

[aishah] 06/11/2017 16:35

A new BUY recommendation in Techinvest. Excellent write-up.

[snape] 06/11/2017 14:19

Aishah
What / where did you read over the weekend?

[aishah] 06/11/2017 09:44

Initial holding this am. Like what I read over the weekend.

[turbocharge] 02/11/2017 17:14

Short-Term Bullish Double Moving Average Crossover (21-day 50-day) generated on 26 Oct 2017

Volume 244,848
Close Price 31.63
Pattern Duration 1 day

[turbocharge] 02/11/2017 17:10

Mercia Technologies will announce its half year results for the six months ending 30 September 2017 on Wednesday, 6 December 2017.

An analyst briefing given by Mark Payton (Chief Executive Officer), Martin Glanfield (Chief Financial Officer) and Matthew Mead (Chief Investment Officer), will be held at 09.30am on the day of the half year results at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.

[p1nkfish] 20/9/2017 07:59

Warwick Audio gets more money along with a Chinese investor.
Comments?

I'm no audiophile. Move into automotive is probably with JLR or Aston or one of the high end bunch.

[turbocharge] 05/9/2017 13:36

Can't be a bad sign if they are recruiting....

hxxps://merciatechnologies.bamboohr.co.uk/jobs/

[turbocharge] 05/9/2017 13:04

Any ideas why the share price is drifting downwards....?

[p1nkfish] 21/8/2017 11:07

25% approx owned by Woodford, why buy this when WPCT (with all its faults) is less volatile. Granted, Mercis hould rise from here but still wpct owns 25%.

[cantrememberthis2] 18/7/2017 13:55

Not going to take much to move it.
GLA

[cantrememberthis2] 18/7/2017 10:31

In at 35.75p looks like a bright spark with nDreams as the push for me to put some chips in.

GLA

[wan] 04/7/2017 11:25

I thought the Results were good and importantly the outlook is encouraging. The discount appears too wide, so I have been adding further to my holding.

[twaintwix] 15/5/2017 11:04

Technology funder chosen to participate in £8.5m accelerator programme

Duncan Tift

15/05/2017
Specialist technology funder Mercia Fund Management is to take part in a new £8.5m pilot scheme looking to provide fledgling firms with a mixture of grant funding and venture capital.

MFM, part of Warwickshire-based Mercia Technologies, is to partner with Innovate UK’s new Investment Accelerator initiative.

Investment is targeted at innovative early stage companies which operate in infrastructure or health and life sciences.

MFM will join six other organisations which will provide private sector investment alongside grants injecting up to £150,000 into successfully selected companies.